Adverse effects: leukopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide may leads to higher adverse events: leukopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Response to treatment (20% improvement)* · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes response to treatment (20% improvement)* compared with methylprednisolone (very low certainty).
1 finding from 1 review
Urinary tract infection · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes adverse events ‐ Urinary tract infections compared with methylprednisolone (very low certainty).
1 finding from 1 review
Adverse events ‐ Death · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes adverse events ‐ Death compared with methylprednisolone (very low certainty).
1 finding from 1 review
SLICC scores (damage index) Scale: from 0 to 48 (lower is better) · patients with neuropsychiatric involvement in systemic lupus erythematosus
1 finding from 1 review
Disease activity · patients with neuropsychiatric involvement in systemic lupus erythematosus
1 finding from 1 review
Prednisone sparing · patients with neuropsychiatric involvement in systemic lupus erythematosus
1 finding from 1 review
Seizures · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes seizures compared with methylprednisolone (very low certainty).
1 finding from 1 review
Dialysis · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in dialysis at end of study compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Remission · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in remission at 6 months compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Recurrence of hyperthyroidism (relapse) [measured by serum thyroid hormone levels above the normal range after withdrawal of methimazole or end of radioiodine treatment] · adults with renal vasculitis
Pulse cyclophosphamide may leads to higher relapse at the end of compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events ‐ treatment failure · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in adverse events ‐ treatment failure compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Serious infections · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in serious infections compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Death at final · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in death at final compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Serum creatinine (mg/dL) · adults with renal vasculitis
1 finding from 1 review
Relapse · SSNS in children
Cyclophosphamide showed no clear difference in relapse at 12 months compared with chlorambucil (low certainty).
1 finding from 1 review
Clinical relapse · SSNS in children
Cyclophosphamide showed no clear difference in relapse at 24 months compared with chlorambucil (low certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: lymphopenia · SSNS in children
Cyclophosphamide may leads to lower adverse effects: lymphopenia compared with chlorambucil (low certainty).
1 finding from 1 review